ID   MS-EwS-6
AC   CVCL_A0VN
SY   MS-PES-6
DR   Wikidata; Q108820994
RX   PubMed=29464090;
RX   PubMed=30879952;
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (Direct_author_submission).
CC   Miscellaneous: Gene fusion, site of sampling and age of donor from personal communication of Rossig, Claudia.
CC   Derived from site: Metastatic; Thoracic cavity; UBERON=UBERON_0002224.
ST   Source(s): PubMed=30879952
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,13
ST   D16S539: 8,11
ST   D3S1358: 14
ST   D5S818: 13
ST   D7S820: 12,13
ST   FGA: 20,24
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=29464090; DOI=10.18632/oncotarget.23815; PMCID=PMC5814230;
RA   Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W.,
RA   Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M.,
RA   Meltzer J., Farwick N., Greune L., Rossig C.;
RT   "T cell infiltration into Ewing sarcomas is associated with local
RT   expression of immune-inhibitory HLA-G.";
RL   Oncotarget 9:6536-6549(2018).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014; PMCID=PMC6520468;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//